13/03/18 -"With multiple myeloma milestones largely coming to an end, we have lowered our out-year revenue estimates slightly. Also, as Genmab is investing aggressively in R&D in search of life beyond Darzalex ..."
Pages
49
Language
English
Published on
13/03/18
You may also be interested by these reports :
25/04/24
The Q1 results topped expectations, led by robust performances across all the key segments. While the management maintained its 2024 guidance, an ...
25/04/24
Q1 results surpassed expectations, on the back of a strong showing from immunology drug Dupixent, RSV vaccine Beyfortus and the new launches of ...
24/04/24
The Q1 sales met the street’s expectations, although forex, off-patent drugs’ generic/biosimilar erosion and declining COVID-19 sales adversely ...
24/04/24
Ipsen started 2024 on a positive note with sales ahead of the company-compiled consensus. Double-digit growth was led by Neuroscience, Oncology, and ...